The POPLAR [14] and OAK [16] studies involved the anti-PD-L1 antibody (atezolizumab) versus the second-line chemotherapy docetaxel for previously treated advanced NSCLC, while anti-PD-1 antibodies (nivolumab and pembrolizumab) were involved in the CheckMate-057 [12], CheckMate-017 [13] and KEYNOTE-010 [15] studies. The gene discussed is CD274; the disease is non-small cell lung carcinoma.